Targeted therapy has been widely demonstrated as an effective strategy to treat cancers,the leading cause of death in the world.This minireview summarizes the technical platforms and methodologies utilized to develop ...Targeted therapy has been widely demonstrated as an effective strategy to treat cancers,the leading cause of death in the world.This minireview summarizes the technical platforms and methodologies utilized to develop and engineer therapeutic monoclonal antibodies and antibody-drug conjugates.First,the USA FDA approved monoclonal antibody(mAb)-based targeted therapies are reviewed.Then the representative innovative chimeric,humanized and fully human anti-cancer antibodies and antibody-drug conjugates are described.Finally,the past and predictive market trend of therapeutic antibodies is discussed.展开更多
Due to the special physiological and pathological characteristics of gliomas,most therapeutic drugs are prevented from entering the brain.To improve the poor prognosis of existing therapies,researchers have been conti...Due to the special physiological and pathological characteristics of gliomas,most therapeutic drugs are prevented from entering the brain.To improve the poor prognosis of existing therapies,researchers have been continuously developing non-invasive methods to overcome barriers to gliomas therapy.Although these strategies can be used clinically to overcome the blood-brain barrier(BBB),the accurate delivery of drugs to the glioma lesions cannot be ensured.Nano-drug delivery systems(NDDS)have been widely used for precise drug delivery.In recent years,researchers have gathered their wisdom to overcome barriers,so many well-designed NDDS have performed prominently in preclinical studies.These meticulous designs mainly include cascade passing through BBB and targeting to glioma lesions,drug release in response to the glioma microenvironment,biomimetic delivery systems based on endogenous cells/extracellular vesicles/protein,and carriers created according to the active ingredients of traditional Chinese medicines.We reviewed these well-designed NDDS in detail.Furthermore,we discussed the current ongoing and completed clinical trials of NDDS for gliomas therapy,and analyzed the challenges and trends faced by clinical translation of these well-designed NDDS.展开更多
基金supported by National Institutes of Health R21CA226491-01A1 (X.M.L.),1R01CA238273-01A1 (X.M.L.) and 1R01CA242917-01A1(X.M.L.)
文摘Targeted therapy has been widely demonstrated as an effective strategy to treat cancers,the leading cause of death in the world.This minireview summarizes the technical platforms and methodologies utilized to develop and engineer therapeutic monoclonal antibodies and antibody-drug conjugates.First,the USA FDA approved monoclonal antibody(mAb)-based targeted therapies are reviewed.Then the representative innovative chimeric,humanized and fully human anti-cancer antibodies and antibody-drug conjugates are described.Finally,the past and predictive market trend of therapeutic antibodies is discussed.
基金financial support from National Natural Science Foundation of China(Nos.81903557 and 82074024)Natural Science Foundation of Jiangsu Province(No.BK20190802,China)+3 种基金Natural Science Foundation Youth Project of Nanjing University of Chinese Medicine(No.NZY81903557,China)the Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine(No.2020YLXK019,China)the Natural Science Foundation of the Jiangsu Higher Education Institutions of China(No.19KJB350003,China)College Students’Innovative Entrepreneurial Training Plan Program of Nanjing University of Chinese Medicine(No.202010315XJ040,China)。
文摘Due to the special physiological and pathological characteristics of gliomas,most therapeutic drugs are prevented from entering the brain.To improve the poor prognosis of existing therapies,researchers have been continuously developing non-invasive methods to overcome barriers to gliomas therapy.Although these strategies can be used clinically to overcome the blood-brain barrier(BBB),the accurate delivery of drugs to the glioma lesions cannot be ensured.Nano-drug delivery systems(NDDS)have been widely used for precise drug delivery.In recent years,researchers have gathered their wisdom to overcome barriers,so many well-designed NDDS have performed prominently in preclinical studies.These meticulous designs mainly include cascade passing through BBB and targeting to glioma lesions,drug release in response to the glioma microenvironment,biomimetic delivery systems based on endogenous cells/extracellular vesicles/protein,and carriers created according to the active ingredients of traditional Chinese medicines.We reviewed these well-designed NDDS in detail.Furthermore,we discussed the current ongoing and completed clinical trials of NDDS for gliomas therapy,and analyzed the challenges and trends faced by clinical translation of these well-designed NDDS.
